BioSpace News Archive

Marinus Pharmaceuticals, Inc. today announced that management will present and participate during the following conferences in February and March.

Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for musculoskeletal infections, announced today the first subject enrollment in its next Phase 2 study, known as APEX-2 (Abbreviated Protocol for Two Stage Exchange).

OSSIO, Inc., a fast-growing orthopedic fixation technology company, announced the introduction of the new OSSIOfiber® Compression Staple, the next step towards becoming the gold standard in orthopedic fixation.

Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced the appointment of Lin Guey, PhD to the company’s Scientific Advisory Board (SAB).

Greenphire, the global leader in financial lifecycle management for clinical trials, today announced that Greenphire CEO, Jim Murphy, will participate in the panel session “The Critical Role of Planning and Budgeting for Patient Logistics,” and will be exhibiting at booth #406 during SCOPE Summit 2023 taking place February 6-9, 2023 in Orlando.

Therap Services offers a Time Tracking module which is designed to document data over a specific period of time at regular intervals in order to monitor and record multiple activities of individuals.

The Collaborative Trajectory Analysis Project (cTAP), a global coalition in rare disease, has announced evidence to support patient-centric alternatives to the conventional use of genetically matched placebo controls in clinical trials for RNA-editing therapies in Duchenne Muscular Dystrophy (DMD).

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its fourth quarter and full year 2022 financial results on Monday, February 27, 2023.

Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, February 28th, 2023.

Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE: INDV).